Philadelphia Chromosome-Positive Acute Myeloid Leukemia: A Rare Aggressive Leukemia With Clinicopathologic Features Distinct From Chronic Myeloid Leukemia in Myeloid Blast Crisis

Chad Soupir; Jo-Anne Vergilio; Paola Cin; Alona Muzikansky; Hagop Kantarjian; Dan Jones; Robert Hasserjian
April 2007
American Journal of Clinical Pathology;Apr2007, Vol. 127 Issue 4, p642
Academic Journal
We performed a multi-institutional retrospective analysis of the morphologic features, immunophenotype, cytogenetics, and BCR-ABL transcript characterization of cases of Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML). We compared these cases with cases of documented chronic myelogenous leukemia in myeloid blast crisis (CML-MBC). Patients with Ph+ AML were less likely to have splenomegaly or peripheral basophilia and had lower bone marrow cellularity and myeloid/erythroid ratios than patients with CML-MBC. Additional specific cytogenetic abnormalities that typically occur in CML-MBC were less common in Ph+ AML. Of 7 patients with Ph+ AML treated with imatinib mesylate, 6 showed at least a partial hematologic response, but the responses were of a short duration (median, 2.5 months). The median survival of patients with Ph+ AML was 9 months, similar to that of patients with CML-MBC (7 months). Ph+ AML is a rare aggressive acute leukemia with some features distinct from CML-MBC.


Related Articles

  • Developing Target Therapy Against Oncogenic Tyrosine Kinase in Myeloid Maliganacies. Naoe, Tomoki // Current Pharmaceutical Biotechnology;Oct2006, Vol. 7 Issue 5, p331 

    Myeloid malignancies are frequently associated with translocations and mutations of tyrosine kinase genes. Fusion genes involving ABL, ARG, PDGFRs, JAK2, SYK, TRKC, and FGFRs, and gain-of-function mutations of FLT3, KIT and JAK2 have been detected at various rates in myeloproliferative disease...

  • Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT. Ditschkowski, M.; Haferlach, C.; Schulte, C.; Trenschel, R.; Beelen, D. W. // Bone Marrow Transplantation;Aug2009, Vol. 44 Issue 4, p265 

    The article presents a case study of a 69-year-old man who have undergone bone marrow transplantation (BMT) in November 1991 from HLA-B-Ag mismatched sister for first chronic phase Ph-positive chronic myeloid leukemia (CML). He obtained cytogenetic remission until a relapse happened in July...

  • just in. McBride, Deborah // ONS Connect;Jun2011, Vol. 26 Issue 6, p6 

    The article offers news briefs related medical studies. It reports on a research regarding a new biomarker accurate in detecting proteins secreted from tumors caused by asbestos exposure. A study revealed that proportion of second cancers associated with radiotherapy treatment for a first cancer...

  • Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor. Kayastha, Gyan K.; Gurung, Padma; Acharya, Paras K.; Paudyal, Buddhi P.; Hayes, Bruce; Zimmerman, Mark; Karki, Arjun; Mansfield, Aaron S. // BMC Blood Disorders;2010, Vol. 10, p8 

    Background: Chronic Myeloid Leukemia (CML) is caused by the abnormal fusion protein BCR-ABL1, a constitutively active tyrosine kinase and product of the Philadelphia chromosome. Gleevec (Imatinib mesylate) is a selective inhibitor of this kinase. Treatment with this agent is known to result in...

  • CHRONIC MYELOID LEUKAEMIA IN HUSM IN THE ERA OF TARGETED THERAPY. Dzarr A., Abu; Hassan, Rosline; P., Thanaseelan; Ghazali, Selamah; AlwI, Zilfahlil; Ankathil, Ravindran; Husin, Azlan; Baba, Abdul Aziz // Malaysian Journal of Medical Sciences;Jan2007 Supplement, Vol. 14, p100 

    Introduction: The Philadelphia chromosome, a genetic abnormality involving reciprocal transfer of ABL genes at chromosome 9q31-34 with BCR region at chromosome 22q has been recognized since the 1960's. The introduction of imatinib mesylate (Glivec) which inhibits the over expressed tyrosine...

  • Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Hochhaus, A.; Baccarani, M.; Deininger, M.; Apperley, J. F.; Lipton, J. H.; Goldberg, S. L.; Corm, S.; Shah, N. P.; Cervantes, F.; Silver, R. T.; Niederwieser, D.; Stone, R. M.; Dombret, H.; Larson, R. A.; Roy, L.; Hughes, T.; Müller, M. C; Ezzeddine, R.; Countouriotis, A. M.; Kantarjian, H. M. // Leukemia (08876924);Jun2008, Vol. 22 Issue 6, p1200 

    Dasatinib, a potent inhibitor of BCR-ABL in vitro, is effective for patients with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. To provide a more definitive assessment of dasatinib in chronic-phase (CP)-CML, we report extended follow-up of a phase II trial, presenting...

  • Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia. Bradbury, C; Houlton, A E; Akiki, S; Gregg, R; Rindl, M; Khan, J; Ward, J; Khan, N; Griffiths, M; Nagra, S; Hills, R; Burnett, A; Russell, N; Vyas, P; Grimwade, D; Craddock, C; Freeman, S D // Leukemia (08876924);Apr2015, Vol. 29 Issue 4, p988 

    A letter to the editor is presented that discusses prognostic value of monitoring immunophenotypic leukaemic stem and progenitor cell population in patients allografted for acute myeloid leukaemia.

  • Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years. Huang, S-Y; Tang, J-L; Jou, S-T; Tsay, W; Hu, C-H; Lin, D-T; Lin, K-S; Wang, C-H; Chen, Y-C; Shen, M-C; Tien, H-F // Leukemia (08876924);Oct99, Vol. 13 Issue 10, p1506 

    Acute myeloid leukemia (AML) with minimal differentiation was usually referred to as acute undifferentiated leukemia in the past. With the help of immunophenotyping, this subtype of leukemia was shown to express myeloid antigens on the blasts and was designated AML-M0 by FAB Cooperative Study...

  • Immunotherapy for Myeloid Leukemia.  // Current Medical Literature: Leukemia & Lymphoma;2011, Vol. 19 Issue 1, p1 

    The article discusses the potential use of immunotherapy for myeloid leukemias. A brief background on chronic myeloid leukemia (CML) and acute promyelocytic leukemia (APL) is presented. Particular focus is given to clinical trials which evaluated peptide-based vaccines in CML. A study of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics